Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ design
- 1 March 1995
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 60 (3), 267-274
- https://doi.org/10.1016/0304-3959(94)00121-t
Abstract
Because a variety of mechanisms may generate pain in neuropathic pain syndromes, conventional clinical trial methods may fail to identify some potentially useful drugs; a drug affecting just a single mechanism may work in too few patients to yield a statistically significant result for the trial. To test a previous clinical observation that approximately one-quarter of patients with painful diabetic neuropathy appear responsive to clonidine, we conducted a formal clinical trial of transdermal clonidine in painful diabetic neuropathy patients using a 2-stage enriched enrollment design. In the first stage (study I), 41 patients with painful diabetic neuropathy completed a randomized, 3-period crossover comparison of transdermal clonidine (titrated from 0.1 to 0.3 mg/day) to placebo patches. Twelve apparent responders from study I were entered into the ‘enriched enrollment’ second stage (study II), consisting of an additional 4 double-blind, randomized, 1-week treatment periods with transdermal clonidine and placebo. Study I showed that in the overall group of 41 patients, pain intensity differed little during clonidine and placebo treatment. In study II, however, the 12 apparent responders from study I had 20% less pain with clonidine than placebo (95% confidence interval (CI): 4–35% pain reduction; P = 0.015), confirming that their pain was responsive to clonidine. None of the 3 consistent clonidine responders who were tested with the α-adrenergic blocker phentolamine had relief of pain, suggesting that clonidine's pain relief is not mediated by a decrease in sympathetic outflow. A post-hoc analysis of many variables suggested that patients who described their pain as sharp and shooting may have a greater likelihood of responding to clonidine. The results of this study support the hypothesis that there is a subset of patients with painful diabetic neuropathy who benefit from systemic clonidine administration and illustrate the value of an enriched enrollment technique in analgesic trials.Keywords
This publication has 35 references indexed in Scilit:
- SINGLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY CROSS-OVER COMPARISON OF EXTRADURAL AND I.V. CLONIDINE IN CHRONIC PAINBritish Journal of Anaesthesia, 1993
- A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's DiseaseNew England Journal of Medicine, 1992
- Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained painPain, 1991
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Pain due to peripheral nerve damageNeurology, 1984
- The natural history of acute painful neuropathy in diabetes mellitus.Journal of Neurology, Neurosurgery & Psychiatry, 1983
- Narcotic Analgesia: Fentanyl Reduces the Intensity But Not the Unpleasantness of Painful Tooth Pulp SensationsScience, 1979
- Validity and sensitivity of ratio scales of sensory and affective verbal pain descriptors: Manipulation of affect by diazepamPain, 1978
- Ratio scales of sensory and affective verbal pain descriptorsPain, 1978
- Painful Diabetic NeuropathyArchives of Neurology, 1976